Summary
The statements focus on a discount/coupon and pricing/eligibility details, none of which are supported by the provided FDA-approved prescribing information excerpts. No accurate on-label medication use, dosing, contraindications, or safety claims were evaluated from the AI-generated content provided.
Category Scores
Accurate Statements
Zerbaxa is also known as ceftolozane/tazobactam.
Not stated in the provided excerpts, but this equivalence is consistent with the labeling excerpt title/content showing ZERBAXA (ceftolozane and tazobactam).
Zerbaxa is an injectable antibiotic combination.
The excerpts describe ZERBAXA as 'for injection' and include 'ceftolozane and tazobactam' with indications for bacterial infections.
Zerbaxa is used to treat bacterial infections.
Supported generally by the 'Indications and Usage' excerpts describing treatment of cIAI, cUTI, and HABP/VABP caused by susceptible microorganisms and the statement to use only for proven/suspected bacterial infections.
Unsupported Statements
The Zerbaxa coupon is a discount program that helps patients pay for Zerbaxa.
No coupon/discount program information appears in the provided prescribing information excerpts.
Patients can obtain a Zerbaxa coupon through the manufacturer's patient assistance program.
No patient assistance/coupon procurement details appear in the provided prescribing information excerpts.
The manufacturer's patient assistance program provides discounts for eligible patients.
No patient assistance program or discount program details appear in the provided prescribing information excerpts.
The manufacturer's patient assistance program is available in the United States.
No country/region availability information appears in the provided prescribing information excerpts.
Eligibility for the Zerbaxa coupon requires meeting certain income requirements.
No eligibility criteria (income or otherwise) appear in the provided prescribing information excerpts.
Eligibility for the Zerbaxa coupon requires being uninsured or underinsured.
No eligibility criteria appear in the provided prescribing information excerpts.
Eligibility for the Zerbaxa coupon requires having a condition that puts patients at higher risk for infections.
No coupon eligibility criteria appear in the provided prescribing information excerpts.
Eligibility for the Zerbaxa coupon requires having a diagnosis that requires the use of Zerbaxa.
No coupon eligibility criteria appear in the provided prescribing information excerpts.
Patients can obtain a Zerbaxa coupon by contacting the manufacturer's patient assistance program directly.
No coupon acquisition steps appear in the provided prescribing information excerpts.
Patients can obtain a Zerbaxa coupon by visiting the manufacturer's website.
No coupon acquisition steps or website information appear in the provided prescribing information excerpts.
To obtain a Zerbaxa coupon, patients need to provide information about income, health insurance, and medical condition.
No coupon application/required documentation details appear in the provided prescribing information excerpts.
The cost of Zerbaxa without a coupon can range from $3,000 to $4,000 per treatment course.
No pricing or cost information appears in the provided prescribing information excerpts.
Contradictions
Important Omissions
On-label prescribing details that would be relevant to safety/appropriate use (e.g., specific FDA-approved indications with organism limits; recommended dosing regimen; renal dosing/monitoring; contraindications; key warnings/precautions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported coupon/pricing/eligibility statements are not clinical prescribing information and were not used to make dosing/safety claims in the provided AI content. However, presenting non-label financial/access claims without label support could mislead users about access and cost.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Coupon/discount program and pricing/eligibility/cost claims are not supported by the provided FDA-approved prescribing information excerpts.
Suggested Improvement
Remove coupon/patient-assistance/pricing/eligibility statements unless supported by the provided FDA label text; restrict claims to information present in the provided prescribing information (e.g., indications, dosing/administration, contraindications, and labeled warnings/precautions).